Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology · 2026 · PMC13321883 · PMID 42366526

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A trend toward longer OS was also observed in patients with favorable/intermediate IMDC risk compared with those with poor IMDC risk, although the difference did not reach statistical significance (Supplementary Figure 2D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.